Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Smith, Kline & French Stories

2012-02-07 06:51:00

LONDON, February 7, 2012 /PRNewswire/ -- In an online video interview with MerchantCantos, GlaxoSmithKline CEO Sir Andrew Witty talks about the pharmaceutical group's special dividend, solid results and why the company is so well positioned to continue to deliver. Sir Andrew said "adversity isn't all downside for everybody" and that the market offered opportunities for companies who had strengthened and had changed their exposure to places of growth. "This is a...

2011-11-10 10:15:00

TORONTO, Nov. 10, 2011 /PRNewswire/ - GlaxoSmithKline Inc. (GSK) today announced the launch of the GSK Canada Life Sciences Innovation Fund, a new national $50 million fund that will significantly advance the commercialization of scientific innovation in Canada by investing in early stage breakthrough research. The fund will identify strategic investment opportunities within Canada's life sciences industry including academic and health institutions, translational research centres and...

2011-11-10 08:00:00

PRINCETON, N.J., Nov. 10, 2011 /PRNewswire/ -- Signum Biosciences, Inc., a privately held biotechnology company, has entered into an agreement with GlaxoSmithKline (China) R&D Company Limited (GSK) to collaborate on Signum's phosphatase screening technology and Phosphoprotein Phosphatase 2A (PP2A). The agreement provides Signum with research support and milestone payments. GSK receives the exclusive right of Signum's proprietary phosphatase screening technology for GSK's research and...

2011-10-19 11:50:00

ELLICOTT CITY, Md., Oct. 19, 2011 /PRNewswire/ -- The Site Solutions Summit, an annual conference of premier clinical research sites from around the world, awarded the 2011 Site Solutions Summit Eagle Awards to GlaxoSmithKline (GSK) as the top pharmaceutical sponsor; to Medpace as the top contract research organization (CRO); and to Quorum Review IRB as the top institutional review board (IRB). Nearly 400 sites voted via confidential ballots to select this year's Site Solutions Summit...

2011-10-19 07:38:00

STEVENAGE, England, October 19, 2011 /PRNewswire/ -- Stakeholder representative to guide development of UK's first open innovation bioscience campus Stevenage Bioscience Catalyst (SBC), the UK's first open innovation bioscience campus, is pleased to announce that Ian Tomlinson, Senior Vice President, Head of Biopharmaceuticals R&D and Worldwide Business Development at GlaxoSmithKline, has been appointed to its Board. In his role as GSK Representative Director,...

2011-08-10 08:00:00

LONDON and OXFORD, England, Aug. 10, 2011 /PRNewswire/ -- Enigma Diagnostics Limited (Enigma) and GlaxoSmithKline (GSK) today announced that they have signed agreements for the supply and commercialization on an exclusive basis of the Enigma® ML system in Europe and other designated key countries, including India, Brazil and Russia. The agreements include development by Enigma of an initial range of respiratory tests for use on its real-time Polymerase Chain Reaction (PCR)...

2011-07-18 12:10:00

WASHINGTON, July 18, 2011 /PRNewswire/ -- At a White House meeting today with President Obama and US business leaders to address education reform, GlaxoSmithKline (GSK) pledged to contribute $10 million toward education over the next five years, with at least one-third of the funds going toward drop-out prevention in the lowest performing schools in the United States. This commitment continues the company's long-term support of science education, literacy skills, teacher development, and...

2011-07-05 08:00:00

RESEARCH TRIANGLE PARK, N.C., July 5, 2011 /PRNewswire/ -- GlaxoSmithKline (NYSE: GSK) today announced that it has implemented the next phase of its new incentive compensation program for professional sales representatives with the introduction of a new performance evaluation methodology and process. In January 2011, GSK eliminated individual sales goals as part of the company's incentive compensation program for sales professionals who work directly with healthcare professionals....

2011-04-18 07:00:00

LONDON, RESEARCH TRIANGLE PARK, N.C. and MISSISSAUGA, Ontario, April 18, 2011 /PRNewswire/ -- GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) submitted the response on 15 April 2011 to the U.S. Food and Drug Administration (FDA) Complete Response letter received on 30 November 2010 for the New Drug Application (NDA) for ezogabine*. Ezogabine is an investigational anti-epileptic drug being studied for the adjunctive treatment of adults with...

2011-02-24 07:30:00

NAPERVILLE, Ill., Feb. 24, 2011 /PRNewswire/ -- GlaxoSmithKline (GSK), one of the world's leading pharmaceutical companies, has received the 2010 Environmental Stewardship Award from Nalco Company (NYSE: NLC) in recognition of GSK's ongoing efforts to reduce its climate change impact and energy and water use. (Logo: http://photos.prnewswire.com/prnh/20101231/NALCOLOGO) The Environmental Stewardship Award recognizes exceptional performance in achieving sustainability objectives and...